EVENTS | VIEW CALENDAR
Proteome Sciences, Thermo Fisher Scientific begin mass spec agreement
COBHAM, United KingdomóProteome Sciences has announced the signing of a technology agreement with Thermo Fisher Scientific Inc., worth a total of $2.1 million, for the development of advanced methods to profile changes in key cancer pathways. Under the terms of the agreement, Proteome Sciences will grant Thermo Fisher access to its patents for a three-stage mass spectrometry fragmentation methodology for improved analysis and accuracy. In return, Proteome Sciences will receive cash as well as a no-cost lease from Thermo Fisher for mass spectrometry equipment for Proteome Sciences to develop the pathway assays. Proteome Sciences will also continue to develop advanced 20- and 30-plex Tandem Mass Tags for Thermo Fisher for the next additions to the Tandem Mass Tags product range.
"Our agreement with Thermo Fisher sets a new benchmark to establish and apply novel diagnostic and prognostic strategies in healthcare management," Christopher Pearce, CEO of Proteome Sciences, said in a press release. "It has long been our goal to provide clinicians the tools they need to provide early diagnosis of disease and better match molecular targeting medicines to the most likely responders. The output from this agreement should have a profound positive impact on the lives of large numbers of patients suffering from chronic diseases and, at the same time, provide considerable economic benefits to the health care system."
The three-stage MS Tandem Mass Tag mass spectrometry technique is a mass spectrometry-based workflow that enables mass spectrometers to simultaneously determine the relative quantitation of proteins in multiple samples with improved accuracy. The workflow is applicable for drug discovery as well as biomarker discovery, clinical analysis and early disease detection/prognosis. Proteome Sciences will makes use of its Tandem Mass Tags and Orbitrap technology to develop a wider range of mass spectrometry assays, and through its SysQuant workflows, will profile the low-level changes in activity demonstrated by key cancer signaling pathways in order to help enable better drug selection for a range of solid tumors.
"Life sciences researchers today need to perform high-quality relative quantitation of many samples quickly," said Ian Jardine, chief technology officer of Chromatography and Mass Spectrometry at Thermo Fisher Scientific. "MS3 TMT technology greatly improves quantitative accuracy and throughput, while Orbitrap technology dramatically increases depth and quality of data. This agreement offers customers a new paradigm in proteomics research."
"We are at a critical juncture toward the development of personalized medicine which requires high-resolution maps of the protein networks regulating disease," Dr. Ian Pike, chief operating officer at Proteome Sciences, commented in a statement. "The combination of the highest sample multiplexing rates from TMT with the industry-leading Thermo Scientific Orbitrap mass spectrometer enables us to provide an unrivaled platform to investigate subtle but significant changes in the proteome."
SOURCE: Proteome Sciences press release